VT
RPRX icon

Vise Technologies’s Royalty Pharma RPRX Stock Holding History

Vise Technologies’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$412K Hold
10,651
– – 0.01% 983
2025
Q4 		$412K Buy
10,651
+1,822
+21% +$69.5K 0.01% 989
2025
Q3 		$312K Sell
8,829
-612
-6% -$22.2K 0.01% 869
2025
Q2 		$340K Buy
+9,441
New +$313K 0.01% 795

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vise Technologies's RPRX Position: Q1 2026 in Review

Vise Technologies held its Royalty Pharma (RPRX) position steady in Q1 2026 at 10,651 shares worth $412K. The position accounts for 0.01% of the portfolio, ranked #983.

Vise Technologies first reported a position in RPRX in Q2 2025 and has held it in 4 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Vise Technologies held 10,651 shares of Royalty Pharma worth $412K as of Q1 2026.
  • Vise Technologies left its Royalty Pharma share count unchanged in Q1 2026.
  • Royalty Pharma made up 0.01% of Vise Technologies's portfolio in Q1 2026, its #983 holding.
  • Vise Technologies first reported a position in Royalty Pharma in Q2 2025 and has held it in 4 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Vise Technologies's 13F filing for Q1 2026, filed 21 Apr 2026.